Dr Boxiong Tang | Senior Director
Teva Pharmaceuticals United State of America

Dr Boxiong Tang, Senior Director, Teva Pharmaceuticals United State of America

Dr. Tang is the Senior Director and Head, Growth Markets of Global Health Economics and Outcomes Research (GHEOR) at Teva Pharmaceutical, responsible for health outcomes research in developing countries and Asia region. Dr. Tang has established the newly created Growth Markets Market Access and HEOR team within Teva.  Previous, Dr. Tang was a Senior Director of Health Outcomes Research at Pfizer Emerging Markets supporting Asia region. His responsibilities includes developing and implementing research strategies in clinical development (specialized in health economics assessment and patient reported outcomes, product value dossiers), and post market products (real world and large database creation and analysis). Dr. Tang is specialized in therapeutic areas of oncology, hematology, and immunology (biologics), and women’s health.  Prior to Pfizer, Dr. Tang was the director of Health Economics and Clinical Outcomes Research in Johnson & Johnson and GlaxoSmithKline, where he was responsible for health outcomes research in biologics and oncology. He is also an adjuvant professor of China Fudan University and faculty of Zhejiang University Medical School. Meanwhile, Dr. Tang is the current Chair of the Health Technology (Industry) Committee, Asia Consortium of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR). Dr. Tang’s training includes a MD in Preventive Medicine, a PhD in Health Services Research, and a MPH in Health Planning and International Health. He has over 20 years’ experiences in medicine, public health, and health economics and outcomes research. He has published more than 30 manuscripts in peer review journals, 80+ abstracts and numerous speeches and presentations in major scientific congresses including ISPOR. He is knowledgeable in the development of Health Technology Assessment around the world. In addition, he served at Scientific Committees of International Health Economics Association (iHEA), Society for Medical Decision Making (SMDM), and a Peer Reviewer of America Journal of Managed Care.


Pharma Pricing & Market Access USA Day 2 @ 12:00

Developing a successful market access strategy in biologic and biosimilar development.

  • Review the development and trends of biologic and biosimilar from the payer’s perspective
  • Different opportunities and challenges of biologic vs biosimilar and chemical brands vs generics
  • Review the evidence needs and role of HEOR in the development of biologics and biosimilar

back to speakers